PubRank

99mTc-MIP-1404 for Imaging Prostate Cancer: Phase I Clinical Study to Assess the Image Quality of a Simplified Kit Formulation Compared to a Multi-step Preparation of 99mTc-MIP-1404

Clinical Trial ID NCT01654874

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01654874

Top papers

Rank Title Journal Year PubWeight™‹?›
1 OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005 7.25
2 Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 2004 3.49
3 SAAM II: Simulation, Analysis, and Modeling Software for tracer and pharmacokinetic studies. Metabolism 1998 2.65
4 In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res 2000 1.91
5 Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res 1996 1.88
6 Physical models and dose factors for use in internal dose assessment. Health Phys 2003 1.85
7 Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer 1998 1.61
8 Clinical trials of cancer therapies targeting prostate-specific membrane antigen. Rev Recent Clin Trials 2007 1.43
9 Is prostate-specific membrane antigen a multifunctional protein? Am J Physiol Cell Physiol 2005 1.31
10 Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg 2006 1.23
11 Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu? J Nucl Med 2005 1.10
12 Targeted treatment of prostate cancer. J Cell Biochem 2007 1.03
13 Targeting novel antigens for prostate cancer treatment: focus on prostate-specific membrane antigen. Expert Opin Ther Targets 2005 1.01
14 Computer package for the calculation of the radiation dose to patients, based on the MIRD approach. J Nucl Med 1985 0.75
Next 100